Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · SaaS
Laser Photonics Corporation (NASDAQ:LASE), an emerging directed energy and laser technology platform developing applications for defense, semiconductor, pharmaceutical and industrial markets (the "Company"), today announced that it will release financial results for the third quarter ended September 30, 2026 before market open on Thursday, November 12, 2026. Management will host an investor conference call at 8:00 a.
Oct 22 · 12:31·Newswire.com
Finance · Healthcare
NEEDHAM, Mass., Oct. 22, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel’s legal and compliance functions, including corporate governance, and report to Candel’s President and Chief Executive Officer.
Oct 22 · 12:05·GlobeNewswire
Biotech & pharma
MIRA-55 demonstrated significant pain relief comparable to Celebrex in a 21-day preclinical study of chronic inflammatory pain.
Oct 22 · 12:00·GlobeNewswire
Finance · Biotech & pharma
WOBURN, Mass., Oct. 22, 2026 -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.
Oct 22 · 12:00·GlobeNewswire
Finance · Biotech & pharma
STOUGHTON, Mass., Oct. 22, 2026 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report third quarter 2026 financial results before the market opens on Thursday November 5, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.
Oct 22 · 12:00·GlobeNewswire
Finance · Healthcare
JERSEY CITY, N.J., Oct. 22, 2026 -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.
Oct 22 · 12:00·GlobeNewswire
Healthcare · Biotech & pharma
Research Letter Reports First-in-Human Use of Circular RNA Therapy, with RXRG001 Demonstrating Durable Improvements in Salivary Flow and Patient-Reported Xerostomia Symptoms Single-Dose Treatment Was Well Tolerated with No Dose-Limiting Toxicities Observed in the First Six Patients Across Two Dose Cohorts RXRG001 Recently
Oct 22 · 12:00·Business Wire
Finance · Biotech & pharma
Conference call and audio webcast to be held at 8:30 a.m. ET CHICAGO, October 22, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innova
Oct 22 · 12:00·Business Wire
Biotech & pharma
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE, Italy & GAITHERSBURG, Md., October 2
Oct 22 · 12:00·Business Wire
Finance · Biotech & pharma
BEDFORD, Mass., October 22, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential diseas
Oct 22 · 12:00·Business Wire
Finance · Healthcare
Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation Interim Analysis Results Expected in Q1 2027 MINNEAPOLIS, October 22, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on
Oct 22 · 12:00·Business Wire